Semantic Scholar uses AI to extract papers important to this topic.
A phase I study of the novel DNA topoisomerase-1 inhibitor, TLC388, administered intravenously to patients with advanced solid tumors.
- Journal of clinical oncology : official journal…
e13618 Background: The phase I first-in-human study of TLC388 (Lipotecan) examined the MTD, safety, anti-tumor activity and… (More)
Is this relevant?